The short answer
Specialized menopause care is for women whose health history changes which treatments are safest or most effective, such as living with HIV, a history of breast cancer, early or surgical menopause, or past blood clots. Most still have good options. Clinicians adjust the type, route and dose of treatment, check for interactions, and coordinate with your other specialists.
No advertising or analytics trackers run on Specialized Care pages. Reading them is never linked to your identity. Our privacy pledge
Choose your pathway
Women living with HIV
Hormone therapy is not contraindicated. We check every ART combination for interactions and coordinate with your HIV team.
After breast cancer
Hot flashes, sleep and vaginal symptoms during and after treatment, including tamoxifen and aromatase inhibitors.
Early and premature menopause
Periods stopping before 45, or premature ovarian insufficiency before 40, and why hormone replacement matters.
Surgical menopause
Sudden menopause after both ovaries are removed, including risk-reducing surgery for BRCA.
History of blood clots
Past DVT or pulmonary embolism, clotting conditions, and which treatments may still be options.
More pathways are in development. If your situation is not listed, a Kindr clinician still reviews your full history at every visit.
Who this section is for
- You are living with HIV or another long-term condition that affects medicine choices
- You have had breast cancer or take endocrine therapy
- Your periods stopped before 45, or before 40
- Your ovaries were removed
- You have had a blood clot or have a clotting condition
Why standard care is sometimes not enough
Most menopause guidance is written for the average person reaching menopause around 51 with no major health conditions. When your history is different, a one-size approach can lead to two problems: being told nothing can be done, or being offered something that does not fit. Specialized care avoids both by starting with your specific situation.
What makes these pathways different
- Treatment choices start from your history, not a standard protocol
- Medicine interactions are checked before prescribing
- Route and dose matter: transdermal options are often preferred
- Earlier attention to bone and heart health where risks are higher
- Coordination with your HIV, oncology, surgical or hematology team, with your permission
Questions, answered
Common questions
Can I get menopause treatment if I have a complex medical history?
+
Usually, yes. Conditions like HIV, past breast cancer, early menopause or a history of clots change which treatments are chosen, not whether help is available. A licensed clinician reviews your history first.
Is hormone therapy ever safe with a medical condition?
+
Often. HIV is not a contraindication; early and surgical menopause usually call for replacement; clot history favors transdermal routes or non-hormonal options. Breast cancer usually points toward non-hormonal care.
What are non-hormonal options for menopause?
+
FDA-approved fezolinetant and elinzanetant, certain antidepressants such as venlafaxine, gabapentin, oxybutynin, and cognitive behavioral therapy. The best choice depends on your other medicines and history.
Will Kindr coordinate with my specialist?
+
With your permission. Your HIV clinician, oncologist, surgeon or hematologist stays responsible for that condition, and Kindr shares your menopause plan so everyone works from the same information.
Is my information private?
+
The preparation tools run only in your browser and save nothing. These pages carry no advertising or analytics trackers. Anything shared in a clinical intake is protected health information under HIPAA.
WRITTEN & MEDICALLY REVIEWED BY
Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team, led by Kevin Wolfe, CMO
Kindr’s clinical content is written and reviewed by board-certified clinicians who prescribe hormone therapy every day across all 50 states — menopause-focused physicians, nurse practitioners, and pharmacists working under Kindr Health, Inc.’s organizational clinical oversight. Every page is checked against current NAMS and ACOG guidance, FDA labeling, and the primary literature before publication, then re-reviewed on a rolling schedule when guidance changes.
Organizational NPI 1609792902 · Last reviewed October 5, 2026 · Editorial policy
Educational content only — not a substitute for individual medical advice, diagnosis, or treatment.
SOURCES & REFERENCES
Every clinical claim on this page is sourced.
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society (2022) — The Menopause Society. www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf
- The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society (2023) — Menopause (journal of The Menopause Society). pubmed.ncbi.nlm.nih.gov/?term=2023+nonhormone+therapy+position+statement+North+American+Menopause+Society
- ESHRE Guideline: Management of women with premature ovarian insufficiency — European Society of Human Reproduction and Embryology. www.eshre.eu/Guidelines-and-Legal/Guidelines/Management-of-premature-ovarian-insufficiency
- Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent Breast Cancer (Clinical Consensus) (2021) — American College of Obstetricians and Gynecologists. www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2021/12/treatment-of-urogenital-symptoms-in-individuals-with-a-history-of-estrogen-dependent-breast-cancer
- Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies (Vinogradova Y, et al.) (2019) — BMJ. doi.org/10.1136/bmj.k4810
- Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV: Women with HIV — DHHS, Clinicalinfo.HIV.gov. clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/women-hiv